(MedPage Today) -- A study to be published this week examines the effect of risk factor modification for dementia, and the FDA is scheduled to rule on a novel formulation for the migraine drug rizatriptan. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment